Local administration trials of interleukin-2 for head and neck cancer.
Recombinant interleukin-2 (rIL-2) has been administered locally in 20 patients with head and neck cancer. Two complete responses in lower lip cancer and 1 partial response in lingual cancer have been obtained. Immunohistological study reveals that tumor infiltrating lymphocytes (TILs), including activated T lymphocytes and natural killer cells, are increased after rIL-2 use. Intraarterial chemotherapy, performed subsequently to the local use of rIL-2 results in a dramatic decrease in tumor size within a short time, and a high frequency of CR cases is observed. Local use of rIL-2 is beneficial for treatment of head and neck cancers, and induction immunochemotherapy combining locally used rIL-2 and arterially infused anticancer drugs plays an important role in a multidisciplinary treatment for these cancers.
Saito
T
T
Department of Otorhinolaryngology, Wakayama Medical College, Japan.
Yoda
J
J
Tabata
T
T
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001706:Biopsy; D003131:Combined Modality Therapy; D005260:Female; D006258:Head and Neck Neoplasms / Q000737:chemistry / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007150:Immunohistochemistry; D007261:Infusions, Intra-Arterial; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D016131:Lymphocyte Subsets / Q000737:chemistry; D016246:Lymphocytes, Tumor-Infiltrating / Q000737:chemistry; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012074:Remission Induction
D007376:Interleukin-2